Necrotizing Enterocolitis (NEC)

I. Overview and epidemiology

• NEC is the most common life‑threatening gastrointestinal emergency in neonates, predominantly affecting preterm and low‑birth‑weight infants.
• Incidence: approximately 1–3 per 1,000 live births overall; affects ~7%–11% of very‑low‑birth‑weight (VLBW, <1,500 g) infants in many series.
• Timing: classically occurs after initiation/advancement of enteral feeds, often within the first 2 weeks of feeding but can present earlier or later.
• Risk population: >90% of cases occur in infants <36 weeks gestation or with birth weight <2,000 g; highest risk and mortality among VLBW and extremely low birth weight (ELBW) infants.
• Mortality: variable (commonly cited 10%–50%), highest in smallest, most premature, and surgically treated infants.

II. Pathogenesis — multifactorial model

NEC arises from an interaction of prematurity‑related intestinal immaturity, dysregulated innate immune responses, microbial factors, and hemodynamic/ischemic insults rather than a single cause.

• Key mechanisms:
  • Immature mucosal barrier with impaired repair and increased permeability.
  • Dysbiosis and bacterial translocation; pathogenic colonization triggers exaggerated inflammation.
  • Innate immune activation (notably TLR4 signaling) producing epithelial injury and inflammatory amplification.
  • Ischemia–reperfusion and impaired intestinal microcirculation contributing to transmural necrosis in severe disease.
  • Genetic susceptibility and host factors modulating response to microbes and injury.
• Contributing clinical risk modulators:
  • Feeding practices: rapid advancement, formula (especially hyperosmolar feeds) increase risk; human milk is protective.
  • Perinatal instability: hypoxia, hypotension, blood transfusions, and other stressors may precipitate or worsen disease in susceptible infants.
  • Medications and iatrogenic factors: some associations described (e.g., early H2 blockers), but causality not uniformly established.

III. Risk reduction and modifiable factors

• Human milk (mother’s own or pasteurized donor human milk) reduces NEC risk via immunologic and bioactive components (sIgA, oligosaccharides, growth factors).
• Standardized feeding protocols with cautious advancement lower NEC incidence compared with nonstandardized practices in many studies, especially in extremely preterm infants.
• Probiotics have been associated with decreased NEC and mortality in many randomized trials and meta‑analyses for VLBW infants; implementation requires attention to strain, product quality, and unit policies.

IV. Clinical presentation

• Early, nonspecific signs: temperature instability, apnea, bradycardia, lethargy, and feeding intolerance (increased gastric residuals).
• Gastrointestinal signs: abdominal distension, abdominal wall erythema, abdominal tenderness, visible bowel loops, hematochezia (occult or gross), and bilious gastric residuals.
• Systemic deterioration: sepsis‑like picture, hypotension, metabolic acidosis, thrombocytopenia, neutropenia or leukocytosis, and multi‑organ dysfunction in severe cases.

V. Diagnosis and staging

Modified Bell staging (high‑yield)

Use Modified Bell criteria to stratify severity (suspected → definite → advanced) combining systemic, intestinal, and radiographic signs to guide management and prognosis.

Modified Bell Staging Criteria for Necrotizing Enterocolitis

Essential investigations

• Laboratory: CBC with differential, platelet count, electrolytes, blood gas, blood lactate; blood cultures and other cultures as indicated (urine, endotracheal if intubated).
• Plain abdominal radiographs (minimum 2 views including supine and left lateral decubitus or cross‑table): hallmark findings include pneumatosis intestinalis (intramural gas), portal venous gas, fixed sentinel loop(s), dilated loops, and free intraperitoneal air with perforation.
• Abdominal ultrasound with Doppler (adjunct): can detect intramural gas, portal venous gas, bowel wall thickness and perfusion, free/loculated fluid, and may identify changes earlier than radiographs in some settings.
• Serial clinical and imaging assessments are critical; absence of radiographic pneumatosis does not exclude early NEC when clinical suspicion is high.

VI. Differential diagnosis

• Neonatal sepsis without NEC, spontaneous intestinal perforation (typically earlier and not feeding‑related), intestinal atresia, malrotation with volvulus, Hirschsprung disease with enterocolitis, and noninfectious causes of feeding intolerance.
• Cow’s milk protein intolerance may present later with bleeding but is distinct epidemiologically and clinically from NEC in preterm neonates.

VII. Management

Initial and medical management

• Immediate steps: NPO (bowel rest), gastric decompression with nasogastric tube, IV access, fluid resuscitation, correction of electrolytes, and hemodynamic support as needed.
• Broad‑spectrum IV antibiotics covering gram‑negative enteric organisms and anaerobes (local protocols guide choice and duration) typically started promptly; duration guided by stage and clinical response.
• Parenteral nutrition for caloric and nutrient support while enteral feeds are withheld; central venous access and TPN monitoring as required.
• Close monitoring with serial exams, labs, and imaging to detect progression to advanced disease or perforation.

Surgical indications and options

• Absolute indications: radiographic pneumoperitoneum (free air) indicating perforation, and stool‑ or bile‑stained fluid from diagnostic paracentesis.
• Relative indications: clinical deterioration despite maximal medical care, worsening metabolic acidosis, thrombocytopenia, portal venous gas with instability, progressive abdominal wall erythema, and radiographic signs of transmural necrosis or persistent obstruction.
• Operative approaches:
  • Peritoneal drain placement as temporizing measure in unstable, extremely low birth weight infants.
  • Exploratory laparotomy for resection of necrotic bowel, possible stoma creation (enterostomy) or primary anastomosis when feasible, and directed management of perforation or localized disease.
  • Second‑look laparotomy within 24–48 hours when bowel viability is uncertain.
• Surgical decision‑making balances removing nonviable bowel with preservation of length to minimize short‑bowel syndrome risk; multidisciplinary intestinal rehabilitation referral when extensive resection expected.

VIII. Prevention strategies

• Promote human milk feeding (mother’s milk or pasteurized donor human milk) as first‑line preventive measure where available.
• Implement standardized feeding protocols with cautious advancement schedules, particularly for extremely preterm infants.
• Consider unit‑based probiotic programs in VLBW infants where evidence, product quality, and local policy support use; selection of specific strains and formulations matters.
• Minimize unnecessary early exposure to potential risk modifiers (e.g., avoid unnecessary acid suppression, evaluate transfusion practices) guided by evolving evidence.

IX. Outcomes and complications

• Short‑term complications: perforation, peritonitis, sepsis, intra‑abdominal abscess, and strictures. Strictures occur commonly in survivors and may present weeks later with obstruction.
• Long‑term complications: short‑bowel syndrome and intestinal failure after extensive resections (a leading pediatric cause of intestinal failure), growth failure, feeding difficulties, and adverse neurodevelopmental outcomes that correlate with disease severity, prematurity, sepsis, and prolonged hospitalization.
• Recurrence of NEC is uncommon but possible; overall mortality remains highest among surgically treated patients and the most premature infants.

X. Emerging diagnostics and therapies

• Biomarkers and metabolomic/microbiome profiling are under investigation to allow earlier diagnosis and risk stratification.
• Translational targets focus on modulating TLR4 signaling, enhancing mucosal repair, and restoring protective microbiota; cell‑based and exosome‑based therapies are experimental.
• Probiotic strain‑specific research continues to refine safety and efficacy recommendations for prophylactic use.

XI. Practical clinical pearls

• Treat any neonate with bilious emesis, abdominal distension, or acute clinical deterioration as possibly developing NEC until proven otherwise; initiate NPO, NG decompression, IV access, and neonatal surgical consultation promptly.
• Pneumatosis intestinalis on radiograph is the classic diagnostic sign; portal venous gas and pneumoperitoneum indicate more severe disease and need for urgent surgical assessment.
• Promote human milk, use standardized feeding protocols, and consider probiotic policy informed by local evidence and product quality to reduce NEC incidence in VLBW infants.

XII. High‑yield summary table